Navigation Links
Suzanne Gagnon, M.D. Joins Idis As Chief Medical Officer
Date:3/12/2013

PRINCETON, N.J., March 12, 2013 /PRNewswire/ -- Idis announced today the appointment of Suzanne Gagnon , M.D., as Chief Medical Officer.  Dr. Gagnon takes on responsibility for leading global medical affairs and providing strategic medical and regulatory leadership across all business divisions.  She will also oversee global quality assurance and compliance.

"We are delighted to have Suzanne join us at this exciting time in the global expansion of Idis. Successful managed access programs require alignment among all stakeholders, from R&D though commercial teams to the physicians treating patients," noted Natalie Douglas , CEO of Idis.  "Suzanne brings senior leadership to our team and a unique blend of industry expertise to our customers that will help guide development and implementation of programs that balance stakeholder requirements and effectively address the needs of patients."

The addition of the CMO role and appointment of Dr. Gagnon further strengthens Idis' offering in the US and enhances the Company's ability to deliver patient-centric programs that address the access challenges faced by patients, physicians and companies around the world. 

Dr. Gagnon has more than twenty years leading the medical, regulatory and safety aspects of pharmaceutical product development and has held senior management positions in both academia and in the pharmaceutical and CRO industries.  Formerly CMO and Executive Vice President at ICON Clinical Research for nearly ten years, Dr. Gagnon brings with her senior level experience in medical, regulatory and clinical research operations, as well as safety and risk management expertise.

Dr. Gagnon will be based at Idis' North American headquarters in Princeton, NJ.

About Idis
Idis has 25 years experience of partnering with pharmaceutical and biotechnology companies to create regulatory-compliant, ethical access to medicines for healthcare professionals and their patients with unmet medical needs. Since 1987, Idis has developed and managed access to thousands of medicines from every therapeutic category, impacting the lives of hundreds of thousands of patients in countries around the world. 

Idis leverages decades of experience, regulatory insight, and a thorough understanding of local and global requirements to create access to medicines at every stage of a product's lifecycle from pre-approval to market exit, and in times of unexpected production shortages.

The company's European headquarters are located in Weybridge, United Kingdom, and North American headquarters are located in Princeton, NJ.

For more information about Idis please visit www.idispharma.com.

Contact: Christine Quern
Phone: +1 617 761 6791
Email  Christine.quern@fkhealth.com


'/>"/>
SOURCE Idis
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. New Physician Joins Colorado Center for Reproductive Medicine
2. Sean P. Nolan Joins InterMune as Executive Vice President and Chief Business Officer
3. Founder of Nestle-Acquired Company Joins Prismic Pharmaceuticals
4. Dr. Mickey Urdea Joins Pressure BioSciences Board of Directors
5. Natalie Douglas, CEO of Idis, Joins Global Genes
6. RARE Project Board of Directors
7. Breast Imaging Specialist Dr. Catherine D. Buhler Joins Radiologic Associates of Fredericksburg
8. Stephen Ondra, M.D., Joins Health Care Service Corporation As Enterprise Chief Medical Officer
9. Attorney Ellen Presby Joins The Nemeroff Law Firm In Dallas
10. Kevin Johnson Joins United Allergy Services Board Of Directors
11. Robert Funari Joins NxStage Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... Feb. 10, 2016  CVS Health (NYSE: CVS ... in Santa Clara County, CA , ... the Santa Clara University campus. CVS Pharmacy stores and ... patients against the disease. Students at Santa Clara University ... vaccinated. In addition, anyone who has had close contact ...
(Date:2/10/2016)... 10, 2016 Immune Pharmaceuticals Inc. (NASDAQ: ... that it has filed a patent application directed to ... --> --> The ... of Ceplene (histamine dihydrochloride) in combination with immune checkpoint ... the efficacy of Ceplene and IL-2 therapy in patients ...
(Date:2/10/2016)... 10, 2016  Astellas Pharma Inc. (TSE: 4503, President ... that it has successfully completed, through its indirect wholly-owned ... purchase all issued and outstanding shares of common stock ... Paul Wotton , "Ocata") for a price of ... ("Tender Offer"). Astellas commenced the Tender Offer on November ...
Breaking Medicine Technology:
(Date:2/10/2016)... California (PRWEB) , ... February 10, 2016 , ... ... are working together to expand dental health services to the developmentally disabled in ... We Care Dental’s operations to a new facility at 71-949 Highway 111, Suite ...
(Date:2/10/2016)... ... 10, 2016 , ... Compliancy Group LLC is pleased to ... throughout the country. The Guard was specifically designed to handle each element required ... regulatory updates, and compliance coaching. , In addition to meeting the compliance needs ...
(Date:2/10/2016)... CO (PRWEB) , ... February 10, 2016 , ... Dr. ... announce the practice is now accepting new dental patients and families in the North ... exceptional dental care services from cleanings to cosmetic dentistry, and all in the most ...
(Date:2/10/2016)... ... February 10, 2016 , ... AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology ... quarter and full year ended December 31, 2015 on Monday, February 29, 2016 after ... the investment community following the release at 4:30 PM ET. Investors interested in participating ...
(Date:2/10/2016)... ... February 10, 2016 , ... A ... Safety Congress and Expo event March 9-11, 2016. Hosted by Ohio's Bureau of ... , As the longest running and largest worker's compensation event in Ohio, ...
Breaking Medicine News(10 mins):